0001104659-23-103552.txt : 20230925 0001104659-23-103552.hdr.sgml : 20230925 20230925170056 ACCESSION NUMBER: 0001104659-23-103552 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230925 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230925 DATE AS OF CHANGE: 20230925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liquidia Corp CENTRAL INDEX KEY: 0001819576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851710962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39724 FILM NUMBER: 231276447 BUSINESS ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919.328.4400 MAIL ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 8-K 1 tm2326854d1_8k.htm FORM 8-K
0001819576 false 0001819576 2023-09-25 2023-09-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 25, 2023

 

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
     
Delaware 001-39724 85-1710962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)

  

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

 

Item 8.01 Other Events.

 

  On September 25, 2023, Liquidia Corporation, a Delaware corporation (the “Company”), issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) accepted for review the Company’s amendment to the tentatively approved new drug application (NDA) for YUTREPIA (treprostinil) inhalation powder in which the Company is seeking to add the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) to the label. The FDA confirmed the type of resubmission as Class II and has set a Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024.

 

A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference into this Item 8.01.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Exhibit
99.1   Press Release of Liquidia Corporation, dated September 25, 2023.
104   Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

September 25, 2023 Liquidia Corporation
   
  By: /s/ Michael Kaseta
    Name: Michael Kaseta
    Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm2326854d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Logo, company name Description automatically generated

 

FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label

 

·Sets PDUFA goal date of January 24, 2024

 

·If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD

 

MORRISVILLE, N.C., September 25, 2023 - Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s amendment to the tentatively approved new drug application (NDA) for YUTREPIA™ (treprostinil) inhalation powder in which the Company is seeking to add the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) to the label. The FDA confirmed the type of resubmission as Class II and has set a Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024.

 

Dr. Rajeev Saggar, Chief Medical Officer of Liquidia, said: “We are pleased that the FDA has accepted the submission for review with a PDUFA goal date well in advance of the expiration in March 2024 of the new clinical investigation exclusivity granted to Tyvaso®. If this amendment is approved by the FDA, YUTREPIA would be indicated for the treatment of both PH-ILD and pulmonary arterial hypertension.”

 

The FDA tentatively approved YUTREPIA to treat PAH in November 2021 and confirmed that the addition of the PH-ILD indication will not require any new clinical studies. The launch of YUTREPIA in both indications remains subject to the successful resolution of the ongoing litigation with United Therapeutics and final FDA approval. Additionally, the FDA may not grant final approval of the PH-ILD indication until after the new clinical investigation exclusivity granted to Tyvaso expires on March 31, 2024.

 

About YUTREPIA™ (treprostinil) inhalation powder

 

YUTREPIA is an investigational, inhaled dry powder formulation of treprostinil delivered through a convenient, low-resistance, palm-sized device. On November 5, 2021, the FDA issued a tentative approval for YUTREPIA for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. The FDA has confirmed that YUTREPIA may add the indication to treat pulmonary hypertension with interstitial lung disease (PH-ILD) without additional clinical studies. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso (nebulized treprostinil). YUTREPIA was previously referred to as LIQ861 in investigational studies.

 

 

 

 

About pulmonary arterial hypertension (PAH)

 

Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression, and improve quality of life.

 

About pulmonary hypertension associated with interstitial lung disease (PH-ILD)

 

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor three-year survival. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though population growth in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021, when inhaled treprostinil was first approved for this indication.

 

About Liquidia Corporation

 

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

 

Tyvaso® is a registered trademark of United Therapeutics Corporation.

 

 

 

 

Cautionary Statements Regarding Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for FDA approval of the NDA for YUTREPIA or any amendment to the NDA for YUTREPIA, the timeline or outcome related to patent litigation in the U.S. District Court for the District of Delaware or inter partes review proceedings conducted at the PTAB, including any appeals of decisions in any such proceedings, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, including the impact of the coronavirus (COVID-19) outbreak on our Company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact Information for Media & Investors
Jason Adair
Chief Business Officer
919.328.4400
jason.adair@liquidia.com

 

 

 

 EX-101.SCH 3 lqda-20230925.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lqda-20230925_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lqda-20230925_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2326854d1_ex99-1img001.gif GRAPHIC begin 644 tm2326854d1_ex99-1img001.gif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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Sep. 25, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 25, 2023
Entity File Number 001-39724
Entity Registrant Name LIQUIDIA CORPORATION
Entity Central Index Key 0001819576
Entity Tax Identification Number 85-1710962
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 419 Davis Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code 919
Local Phone Number 328-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol LQDA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2326854d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001819576 2023-09-25 2023-09-25 iso4217:USD shares iso4217:USD shares 0001819576 false 8-K 2023-09-25 LIQUIDIA CORPORATION DE 001-39724 85-1710962 419 Davis Drive Suite 100 Morrisville NC 27560 919 328-4400 false false false false Common stock LQDA NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://liquidia.com/role/Cover Cover Cover 1 false false All Reports Book All Reports lqda-20230925.xsd lqda-20230925_lab.xml lqda-20230925_pre.xml tm2326854d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2326854d1_8k.htm": { "nsprefix": "lqda", "nsuri": "http://liquidia.com/20230925", "dts": { "schema": { "local": [ "lqda-20230925.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lqda-20230925_lab.xml" ] }, "presentationLink": { "local": [ "lqda-20230925_pre.xml" ] }, "inline": { "local": [ "tm2326854d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://liquidia.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2326854d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2326854d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-103552-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-103552-xbrl.zip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end